McKesson Corporation (MCK)
NYSE · Healthcare · Medical - Distribution
Profile
McKesson Corporation
- Exchange
- NYSE
- Ticker
- MCK
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Country
- US
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Key facts
McKesson Corporation: key facts
- McKesson Corporation (NYSE: MCK) is a Medical - Distribution company in the Healthcare sector.
- In fiscal 2026, McKesson Corporation reported revenue of $403.4B and net income of $4.8B.
- Revenue grew 11.2% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $411.0B and net income was $4.6B.
MonkScore
McKesson Corporation's MonkScore
MonkScore
MonkScore range: 70–80
as of October 2026
Sector rank: 206 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth70–80
- Profitability80–90
- Quality60–70
- Market Conviction30–40
- Safety40–50
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
McKesson Corporation's annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Revenue | $411.0B | $403.4B | $359.1B | $309.0B | $276.7B | $264.0B |
| Gross profit | $15.0B | $14.6B | $12.5B | $12.2B | $11.9B | $12.6B |
| Operating income | $6.7B | $6.5B | $4.4B | $3.9B | $4.5B | $2.7B |
| Net income | $4.6B | $4.8B | $3.3B | $3.0B | $3.6B | $1.1B |
| Operating cash flow | $6.9B | $6.2B | $6.1B | $4.3B | $5.2B | $4.4B |
| Capital expenditure | -$668.0M | -$745.0M | -$859.0M | -$687.0M | -$558.0M | -$535.0M |
| Free cash flow | $6.2B | $5.4B | $5.2B | $3.6B | $4.6B | $3.9B |
| Total debt | $11.7B | $8.6B | $7.4B | $7.4B | $7.3B | $7.5B |
| Cash | $5.2B | $4.0B | $5.7B | $4.6B | $4.7B | $3.5B |
Revenue growth a year
- 1-year
- 12.4%
- 3-year
- 13.4%
- 4-year
- 11.2%
Compound growth between fiscal years.
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.